Drug intelligence / Profile preview

BSL_EP025

Development stage: Preclinical
Lead developer: Biosearch Life
Administration: Oral

Overview

BSL_EP025 is a combination of plant extracts under investigation as a dietary supplement, primarily intended to reduce LDL-cholesterol and oxidized LDL cholesterol levels in humans, and explored for its effects on blood sugar and HbA1c in type 2 diabetes. The specific composition of the supplement in clinical research includes bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder. Mechanistic action is not specific to a pharmacological target but leverages the bioactive components of the plant extracts for lipid and glycemic regulation[1][3][5].

Brand names: BSL_EP025
Other names: BSL_EP025

Beyond the preview

Go deeper on BSL_EP025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSL_EP025.

Explore the full profile